BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Commonsense Ways to work on Your Funds with a Restricted Pay - 2IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- 3Extraordinary Guinness World Records That Will Astound You
- 4Israeli lawmakers pass bill reviving death penalty for terrorists
- 5The Most Enrapturing Authentic Milestones to Visit
- 'Always put others first': IDF reservist who died while on leave saves four with organ transplants
- Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- Instructions to Explore the Therapy Choices for Cellular breakdown in the lungs
- The Way to Monetary Health: Individual budget Change
- New nesting beach for birds at RSPB reserve
- 5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
- A Manual for Pick Viable Psychological well-being Backing Administrations In 2024
- Surge of off‑lease electric vehicles expected to drive down used EV prices
- What to know about new CDC deputy director who has been critical of COVID vaccines
